We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Nicola
White
n.g.white@ucl.ac.uk
Nicola
White
n.g.white@ucl.ac.uk
Nicola
White
n.g.white@ucl.ac.uk
Malignant neoplasms of ill-defined, secondary and unspecified sitesGeneral symptoms and signs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Background
Pain is commonly experienced by people who are living with advanced (incurable) cancer. There is evidence to suggest virtual reality could help to relieve this pain: however, this evidence is poor quality with the intervention poorly defined.
Aim
To develop and refine a virtual reality intervention that will help people living with advanced cancer to manage pain.
Objectives
1.Explore and establish key components of a virtual reality intervention for people with advanced cancer in terms of effectiveness, acceptability and feasibility using in-depth interviews and focus groups with people living with advanced cancer and experiencing pain.
2.Develop and manualise a virtual reality intervention using co-design methodology.
3.User-test the intervention to refine further.
Methods Multi-method design, over three phases:
Phase I.Focus groups or individual interviews with a total of 40 people, from four locations (Brighton, Cardiff, Liverpool, & London), who have advanced cancer and experience pain. They will use the virtual reality intervention and give feedback on what resonated with them and what they would change.
Phase II.Four focus groups (one at each study location) with multiple stakeholders including: healthcare professionals, technology specialists, and people with lived experience. During this stage, the findings from phase 1 will be presented and a manual will be produced that gives guidelines on use of the virtual reality intervention.
Phase III.Up to 20 people living with advanced cancer and pain will user-test the intervention over an eight-week period. During this phase, we will test if/how often the virtual reality is used as part of routine practice in each site and identify any barriers of use.
Anticipated Impact and Dissemination
1. A robustly co-designed intervention, ready for testing in a larger trial, to assess the clinical and cost effectiveness of virtual reality as a form of pain management.
2. Guidelines for the use of virtual reality in a clinical setting.
The results will be published through academic routes (peer-reviewed publications as well as presented at national and international conferences).
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Patients who have a diagnosis of epilepsy, those who are imminently dying, those who the clinical team feel it would be detrimental to participate, or do not meet the study inclusion will be excluded. Professionals who are not employed by the study location or the virtual reality company will not be eligible to participate. We will document reasons for not participating, where offered.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by University College London and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 56557
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
